Ionis Pharmaceuticals Inc
IONS
Market Cap$5.21B
Close$
$-22.58
169% downside
Current Fair Value
169% downsideOvervalued by 169% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.21 Billion |
|---|---|
| Enterprise Value | $1.23 Trillion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.04 |
| Beta | 0.29 |
| Outstanding Shares | 158,735,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -11.36 |
|---|---|
| PEG | -392.33 |
| Price to Sales | 0.04 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 9.33 |
| Enterprise Value to EBIT | -8.37 |
| Enterprise Value to Net Income | -2692 |
| Total Debt to Enterprise | 1.21 |
| Debt to Equity | 3.13 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Ionis Pharmaceuticals Inc
817 employees
CEO: Brett Monia Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...